A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022.
REUTERS/Mike Blake/File Photo Acquire Licensing RightsCompanies Grail Inc FollowIllumina Inc FollowNov 9 (Reuters) - U.S. genetic testing Illumina (ILMN.O) on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services.
Illumina also disclosed it recognized $712 million in goodwill and $109 million in intangible asset impairment related to the Grail segment, in the quarter.
Illumina sees full-year adjusted profit per share to be between $0.60 and $0.70, versus its prior forecast range of $0.75 to $0.90.
On an adjusted basis, the company earned 33 cents per share during the quarter, versus analysts' estimate of 12 cents per share.
Persons:
Mike Blake, Illumina, Pratik Jain, Shilpi Majumdar
Organizations:
REUTERS, Thomson
Locations:
San Diego , California, U.S, China, Bengaluru